HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2019)... ... ... TIME For Kids (TFK) revealed the first-ever list of the World’s ... that are tailored to the interests of kids. The list identifies The Children’s Museum ... TIME for Kids gathered nominations from its network of TFK Kid Reporters ...
(Date:12/5/2019)... ... December 05, 2019 , ... HealthCareMandA.com is hosting an interesting ... on Thursday, December 12, 2019, at 1:00 PM ET. , Private equity firms ... firms are scrambling to assemble regional platforms with enough scale and talent to ...
(Date:12/4/2019)... ... December 04, 2019 , ... A November 12 ... cities offer them as public transit options. The article highlighted the life-changing or life-ending ... confined to a bed to a rider fatality after an incident with a vehicle. ...
(Date:12/4/2019)... ... ... While the holidays are a time for joy and sharing, they can ... Service specialists. , “There are many behavioral and logistical changes you ... Joyce Cavanagh, AgriLife Extension specialist in family economics, College Station. , Prioritize and plan ...
(Date:12/2/2019)... ... 02, 2019 , ... TrialScope, the global leader in clinical ... American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, to launch ... inform patients, caregivers, the public, patient advocacy groups and healthcare professionals (HCPs) about ...
Breaking Medicine News(10 mins):
(Date:12/4/2019)... ... 2019 , ... The Harm Reduction Institute (HRI) as a part of the ... rehab center and non-profit Intensive outpatient after care (IOP) , has officially ... distributed Naloxone amongst members of the own community in Orange County, CA. , ...
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, a ... Top 17 Master's in Organizational Psychology Degree Programs for 2020. The comprehensive research ... the nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, ...
(Date:12/2/2019)... ... December 02, 2019 , ... TopConsumerReviews.com ... by Native Remedies aimed at supporting Women’s Fertility and healthy natural ovulation. , ... harder for some women than for others. Factors like weight, medical conditions, age, ...
Breaking Medicine Technology:
Cached News: